In this episode, Aniruddha (Anu) Hazra, MD, and Ofole Mgbako, MD, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: Data on drug–drug interactions between PrEP options and gender-affirming hormone therapyContributing factors to inequities in PrEP uptake for Black and Latino individualsData on FTC/TAF PrEP for transgender individualsHow to decide whether to do an oral lead-in before starting injectable cabotegravir PrEPTime to effectiveness after starting PrEP PrEP resources available for transgender communities, especially regarding stigmaIntegration of PrEP with gender-affirming hormone therapyStrategies to increase PrEP uptake, specifically in the southCounseling patients on drug–drug interactions, adverse events, and transmission risk when starting PrEPInvolving PrEP navigators in the care of people receiving PrEPSupporting PrEP adherence and retention in careThe use of DoxyPEP in transgender individuals receiving PrEPFacultyAniruddha (Anu) Hazra, MDAssistant Professor, Section of Infectious Disease and Global HealthDirector, Infectious Diseases Fellowship ProgramMedical Director, UCM Sexual Wellness ClinicDirector of STI Services, Chicago Center of HIV EliminationDepartment of MedicineUniversity of ChicagoChicago, IllinoisOfole Mgbako, MDAssistant Professor of Medicine and Population Health Section Chief of Infectious DiseaseBellevue HospitalClinical Pillar Lead, NYU Institute for Excellence in Health EquityNYU Grossman School of MedicineNYU Langone HealthNew York, New YorkLink to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related